Form 8-K VERU INC. For: Jun 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Veru partners with Novo Nordisk for obesity drug combination study
June 4, 2026 8:42 AM EDTVeru Inc. (NASDAQ: VERU) entered into a clinical supply agreement with Novo Nordisk A/S on June 2, 2026, for the company's Phase 2b PLATEAU clinical study.
The study will evaluate the combination of Veru's enobosarm, an oral selective androgen receptor modulator, with Novo Nordisk's... More
